ArticleParasites & vectors2025
Comparative analysis of cystic echinococcosis burden trends: a systematic evaluation of global and Chinese regional patterns using global burden of disease study 2021 data.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study leveraged the Global Burden of Disease (GBD) 2021 database to comprehensively evaluate the trends in the disease burden of cystic echinococcosis (CE) in China from 1990 to 2021, situating its unique trajectory within the global context to inform targeted control strategies.
methodsBased on data from the GBD 2021 study, the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of CE were analyzed. Joinpoint regression was applied to calculate the average annual percentage change (AAPC), decomposition analysis was conducted to identify key driving factors, and frontier analysis was used to assess reduction potential. Subgroup analyses were stratified by age, sex, and region.
resultsGlobally, the age-standardized incidence rate (ASIR) and age-standardized prevalence rate (ASPR) of CE remained relatively stable from 1990 to 2021. In contrast, China experienced sharp increases in ASIR (AAPC = 2.94%) and ASPR (AAPC = 3.13%). Age-standardized mortality rate (ASMR) and age-standardized DALY rate (ASDR) declined globally and in China, though China's ASDR reduction (AAPC = -2.71%) lagged behind the global rate (AAPC = -4.0%). Decomposition analysis indicated that epidemiological deterioration was the primary driver of increased cases in China, while healthcare improvements contributed to reduced deaths and DALYs. Females had higher incidence and prevalence, particularly among those aged over 35, whereas males exhibited higher mortality and DALYs. The global CE burden was negatively correlated with the Sociodemographic Index (SDI). Although China approached the efficiency frontier in disease control, elevated ASPR and ASDR indicated persistent transmission and latent infections, suggesting further reduction potential.
conclusionsChina faces rising CE incidence and prevalence despite improved outcomes, owing to delayed diagnosis and unbalanced resources. Aging and persistent exposure have worsened the burden, especially among middle-aged adults and females. Strategic priorities include enhanced prevention in the elderly, improved screening for women, intensified management of severe male cases, and balanced treatment/prevention approaches. SDI is a key determinant of CE burden, requiring focused interventions in low-SDI regions. Targeted monitoring of ASPR and ASDR is crucial to reduce the impact of historical transmission and achieve World Health Organization (WHO) targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.